|
1
|
Abramson DH: Retinoblastoma in the 20th
century: past success and future challenges the Weisenfeld lecture.
Invest Ophthalmol Vis Sci. 46:2683–2691. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kim JW, Abramson DH and Dunkel IJ: Current
management strategies for intraocular retinoblastoma. Drugs.
67:2173–2185. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gombos DS and Chevez-Barrios AP: Current
treatment and management of retinoblastoma. Curr Oncol Rep.
9:453–458. 2007. View Article : Google Scholar
|
|
4
|
Varan A, Kiratli H, Aydin B, et al: The
treatment of retinoblastoma with four-drug regimen including
cisplatin, etoposide, vincristine, and cyclophosphamide. Pediatr
Hematol Oncol. 29:529–537. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kim H, Lee JW, Kang HJ, et al: Clinical
results of chemotherapy based treatment in retinoblastoma patients:
a single center experience. Cancer Res Treat. 40:164–171. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Makimoto A: Results of treatment of
retinoblastoma that has infiltrated the optic nerve, is recurrent,
or has metastasized outside the eyeball. Int J Clin Oncol. 9:7–12.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Siddik ZH: Cisplatin: mode of cytotoxic
action and molecular basis of resistance. Oncogene. 22:7265–7279.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rabik CA and Dolan ME: Molecular
mechanisms of resistance and toxicity associated with platinating
agents. Cancer Treat Rev. 33:9–23. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Galluzzi L, Senovilla L, Vitale I, et al:
Molecular mechanisms of cisplatin resistance. Oncogene.
31:1869–1883. 2012. View Article : Google Scholar
|
|
10
|
Koberle B, Tomicic MT, Usanova S and Kaina
B: Cisplatin resistance: preclinical findings and clinical
implications. Biochim Biophys Acta. 1806:172–182. 2010.PubMed/NCBI
|
|
11
|
Shields CL, Mashayekhi A, Au AK, et al:
The International Classification of Retinoblastoma predicts
chemoreduction success. Ophthalmology. 113:2276–2280. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ammar H and Closset JL: Clusterin
activates survival through the phosphatidylinositol 3-kinase/Akt
pathway. J Biol Chem. 283:12851–12861. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wyatt A, Yerbury J, Poon S, Dabbs R and
Wilson M: Chapter 6: the chaperone action of clusterin and its
putative role in quality control of extracellular protein folding.
Adv Cancer Res. 104:89–114. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim JH, Kim JH, Yu YS, Min BH and Kim KW:
Protective effect of clusterin on blood-retinal barrier breakdown
in diabetic retinopathy. Invest Ophthalmol Vis Sci. 51:1659–1665.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim JH, Kim JH, Jun HO, et al: Protective
effect of clusterin from oxidative stress-induced apoptosis in
human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci.
51:561–566. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim JH, Kim JH, Yu YS, Kim DH, Kim CJ and
Kim KW: Establishment and characterization of a novel,
spontaneously immortalized retinoblastoma cell line with adherent
growth. Int J Oncol. 31:585–592. 2007.PubMed/NCBI
|
|
17
|
Kim JH, Kim JH, Yu YS, Min BH and Kim KW:
The role of clusterin in retinal development and free radical
damage. Br J Ophthalmol. 91:1541–1546. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang GF, Li XM and Xie D: Overexpression
of clusterin in ovarian cancer is correlated with impaired
survival. Int J Gynecol Cancer. 19:1342–1346. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Watari H, Kanuma T, Ohta Y, et al:
Clusterin expression inversely correlates with chemosensitivity and
predicts poor survival in patients with locally advanced cervical
cancer treated with cisplatin-based neoadjuvant chemotherapy and
radical hysterectomy. Pathol Oncol Res. 16:345–352. 2010.
View Article : Google Scholar
|
|
20
|
Kim JH, Yu YS, Kim KW and Min BH: The role
of clusterin in in vitro ischemia of human retinal endothelial
cells. Curr Eye Res. 32:693–698. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Burnier MN, McLean IW, Zimmerman LE and
Rosenberg SH: Retinoblastoma. The relationship of proliferating
cells to blood vessels. Invest Ophthalmol Vis Sci. 31:2037–2040.
1990.PubMed/NCBI
|
|
22
|
Lourda M, Trougakos IP and Gonos ES:
Development of resistance to chemotherapeutic drugs in human
osteosarcoma cell lines largely depends on up-regulation of
clusterin/apolipoprotein J. Int J Cancer. 120:611–622. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang H, Kim JK, Edwards CA, Xu Z,
Taichman R and Wang CY: Clusterin inhibits apoptosis by interacting
with activated Bax. Nat Cell Biol. 7:909–915. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Trougakos IP, Lourda M, Antonelou MH, et
al: Intracellular clusterin inhibits mitochondrial apoptosis by
suppressing p53-activating stress signals and stabilizing the
cytosolic Ku70-Bax protein complex. Clin Cancer Res. 15:48–59.
2009. View Article : Google Scholar
|
|
25
|
Hara I, Miyake H, Gleave ME and Kamidono
S: Introduction of clusterin gene into human renal cell carcinoma
cells enhances their resistance to cytotoxic chemotherapy through
inhibition of apoptosis both in vitro and in vivo. Jpn J Cancer
Res. 92:1220–1224. 2001. View Article : Google Scholar
|
|
26
|
Miyake H, Hara I, Kamidono S and Gleave
ME: Synergistic chemsensitization and inhibition of tumor growth
and metastasis by the antisense oligodeoxynucleotide targeting
clusterin gene in a human bladder cancer model. Clin Cancer Res.
7:4245–4252. 2001.
|
|
27
|
Laskin JJ, Nicholas G, Lee C, et al: Phase
I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in
combination with a gemcitabine and platinum regimen in patients
with previously untreated advanced non-small cell lung cancer. J
Thorac Oncol. 7:579–586. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Saad F, Hotte S, North S, et al:
Randomized phase II trial of custirsen (OGX-011) in combination
with docetaxel or mitoxantrone as second-line therapy in patients
with metastatic castrate-resistant prostate cancer progressing
after first-line docetaxel: CUOG trial P-06c. Clin Cancer Res.
17:5765–5773. 2011. View Article : Google Scholar : PubMed/NCBI
|
